Atogepant (Qulipta) vs Ubrogepant (Ubrelvy)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: CGRP receptor · full Migraine pipeline

Atogepant (Qulipta)

Marketed by AbbVie

Approved in Migrainesmall molecule
Reliable signal

NCT03777059 · Phase 3 · completed

The study was randomized, double-blind, and placebo-controlled, with 910 participants and a clinically meaningful primary endpoint based on change in monthly migraine days. The primary comparison was statistically significant in favor of atogepant for 10 mg, 30 mg, and 60 mg doses, each with p<0.0001.

Next expected readout: March 2028 · NCT05711394 (registry estimate)

Reported efficacy

Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Placebo -2.48 migraine days per month (Standard Error 0.21) | Atogepant 10 mg -3.69 migraine days per month (Standard Error 0.21) | Atogepant 30 mg -3.86 migraine days per month (Standard Error 0.206) | Atogepant 60 mg -4.2 migraine days per month (Standard Error 0.206) (met)

Result source: NCT03777059

Ubrogepant (Ubrelvy)

Marketed by AbbVie

Approved in Migrainesmall molecule
Reliable signal

NCT02828020 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial with 1,672 participants. Both ubrogepant doses met both primary clinical endpoints, with statistically significant improvements over placebo in pain freedom and relief of the most bothersome migraine-associated symptom at 2 hours.

Next expected readout: May 2027 · NCT05125302 (registry estimate)

Reported efficacy

Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Placebo 121 Participants | Ubrogepant 100 mg 190 Participants (met)

Result source: NCT04492020

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Atogepant (Qulipta)
Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period (Baseline (Day -28 to Day -1) to Week 12): Placebo -2.48 migraine days per month (Standard Error 0.21) | Atogepant 10 mg -3.69 migraine days per month (Standard Error 0.21) | Atogepant 30 mg -3.86 migraine days per month (Standard Error 0.206) | Atogepant 60 mg -4.2 migraine days per month (Standard Error 0.206) NCT03777059 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period (Baseline (First 28 Days of Screening/Baseline Period) to Week 12): Placebo -2.85 migraine days per month (Standard Error 0.23) | Atogepant 10 mg QD -4 migraine days per month (Standard Error 0.32) | Atogepant 30 mg QD -3.76 migraine days per month (Standard Error 0.23) | Atogepant 60 mg QD -3.55 migraine days per month (Standard Error 0.23) | Atogepant 30 mg BID -4.23 migraine days per month (Standard Error 0.35) | Atogepant 60 mg BID -4.14 migraine days per month (Standard Error 0.33) NCT02848326 · Phase 2/3 · design grade: strong · reviewed ClinicalTrials.gov result
Ubrogepant (Ubrelvy)
Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Placebo 121 Participants | Ubrogepant 100 mg 190 Participants NCT04492020 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Atogepant (Qulipta)'s landscape · Ubrogepant (Ubrelvy)'s landscape